Dupilumab
Dupilumab is a monoclonal antibody medication used to treat moderate-to-severe inflammatory conditions including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. It works by blocking specific proteins (IL-4 and IL-13) that drive type 2 inflammation in the body.
Dupilumab is a biologic injection that treats inflammatory conditions by blocking IL-4 and IL-13 signaling pathways.
Key facts at a glance
- ATC
- D11AH05
- RxNorm
- 1876376
- Generic
- Dupilumab
- Class
- atc-d11
- Brands
- Dupixent
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 300mg every other week (after 600mg initial dose)
- Maximum
- consult physician
- Frequency
- every 2 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 200mg every other week for patients 12-17 years (after 400mg initial dose)
- Maximum
- consult physician
- Frequency
- every 2 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 300mg every other week (after 600mg initial dose)
- Maximum
- consult physician
- Frequency
- every 2 weeks
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
6 groupspregnancy
all trimestersavoid if possible
use only if potential benefit justifies potential risk to fetus
regular prenatal monitoring
Use with caution and monitor for adverse effects.
lactation
breastfeedingno adjustment
decision to discontinue nursing or dupilumab should consider benefit to mother and risk to infant
monitor infant for infections
pediatric_age
6 months to 17 yearsweight-based dosing
approved for atopic dermatitis in patients 6 months and older, asthma in patients 6 years and older, and CRSwNP in patients 12 years and older
regular growth monitoring in pediatric patients
geriatric
65 years and olderno adjustment
no dosage adjustment required for patients 65 years and older
standard monitoring
renal_impairment
mild to moderateno adjustment
no dose adjustment recommended for mild to moderate renal impairment
standard monitoring
hepatic_impairment
mild to moderateno adjustment
use with caution in hepatic impairment due to limited data
monitor liver function tests
Use with caution and monitor for adverse effects.
Statistics and clinical data
FDA approval year
Initial FDA approval for atopic dermatitis
Drug class
Biologic immunomodulator classification
Approved indications
Therapeutic indications
Route of administration
Delivery method
Treats moderate-to-severe atopic dermatitis (eczema), type 2 asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis in patients who haven't responded well to other treatments
As a monoclonal IgG4 antibody, dupilumab specifically binds to the IL-4Rα subunit shared by IL-4 and IL-13 receptors, inhibiting signaling of both cytokines and reducing the inflammatory response that causes symptoms
Administered via subcutaneous injection (typically every 2 weeks), may increase risk of conjunctivitis and hypersensitivity reactions, requires refrigeration, and should not be used with live vaccines. Patients should be monitored for signs of infection or allergic reactions.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy